Zhiyong He

机构：Central South University, Guiyang Medical University, Peking University, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, Peking University First Hospital, Fujian Provincial Cancer Hospital, Xiangya Hospital Central South University, Tianjin Medical University · ORCID：0000-0003-0793-8598

发表论文 81 篇 · 总被引 3690 次 · h-index 26

代表论文

• First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial (2024 · The Lancet Respiratory Medicine · 被引 59)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 27)
• Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial. (2024 · Journal of Clinical Oncology · 被引 14)
• Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES) (2023 · Lung Cancer · 被引 10)
• Magnon interactions in a moderately correlated Mott insulator (2024 · Nature Communications · 被引 8)
• 1348 Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR + NSCLC progressed on EGFR-TKI treatment (2025 · 被引 7)